MHRA approves Filspari for IgAN

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

IgA neuropathy, also known as Berger’s disease, is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in your kidneys. Sparsentan was approved under the International Recognition Procedure (IRP), following/g route B.

The MHRA noted that the active ingredient in Filspari, sparsentan, works by blocking the receptors for two hormones called endothelin and angiotensin. Endothelin and angiotensin play a role in regulating processes in the kidney such as inflammation that lead to progression of kidney damage.